Furthermore, in vivo studies have demonstrated that the intratumoral administration of TMEM16A shRNA can completely impede tumor growth in mice, highlighting the therapeutic potential of targeting this channel in prostate cancer treatments. The gene discussed is ANO1; the disease is Familial prostate cancer.